These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 15285064)

  • 1. New treatment for thyroid ablation as effective as traditional therapy without side-effects of hypothyroidism.
    Rollins G
    Rep Med Guidel Outcomes Res; 2004 Jul; 15(14):10, 12. PubMed ID: 15285064
    [No Abstract]   [Full Text] [Related]  

  • 2. Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant human TSH (rhTSH): a randomized controlled study.
    Taïeb D; Sebag F; Cherenko M; Baumstarck-Barrau K; Fortanier C; Farman-Ara B; De Micco C; Vaillant J; Thomas S; Conte-Devolx B; Loundou A; Auquier P; Henry JF; Mundler O
    Clin Endocrinol (Oxf); 2009 Jul; 71(1):115-23. PubMed ID: 18803678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients.
    Pötzi C; Moameni A; Karanikas G; Preitfellner J; Becherer A; Pirich C; Dudczak R
    Clin Endocrinol (Oxf); 2006 Oct; 65(4):519-23. PubMed ID: 16984246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal.
    Hänscheid H; Lassmann M; Luster M; Thomas SR; Pacini F; Ceccarelli C; Ladenson PW; Wahl RL; Schlumberger M; Ricard M; Driedger A; Kloos RT; Sherman SI; Haugen BR; Carriere V; Corone C; Reiners C
    J Nucl Med; 2006 Apr; 47(4):648-54. PubMed ID: 16595499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of thyroid cancer.
    Blahd WH
    Compr Ther; 1993; 19(5):197-202. PubMed ID: 8275665
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of 131I in the treatment of well differentiated thyroid cancer.
    Woodrum DT; Gauger PG
    J Surg Oncol; 2005 Mar; 89(3):114-21. PubMed ID: 15719384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How the availability of recombinant human TSH has changed the management of patients who have thyroid cancer.
    Schlumberger M; Ricard M; De Pouvourville G; Pacini F
    Nat Clin Pract Endocrinol Metab; 2007 Sep; 3(9):641-50. PubMed ID: 17710085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure.
    Driedger AA; Quirk S; McDonald TJ; Ledger S; Gray D; Wall W; Yoo J
    Clin Nucl Med; 2006 Aug; 31(8):454-7. PubMed ID: 16855429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follow-up of differentiated thyroid carcinoma.
    Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B
    Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.
    Luster M; Lippi F; Jarzab B; Perros P; Lassmann M; Reiners C; Pacini F
    Endocr Relat Cancer; 2005 Mar; 12(1):49-64. PubMed ID: 15788638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Classification of the malignant struma and its combined treatment].
    Röher HD
    Med Welt; 1969 Jun; 26():1480-4. PubMed ID: 5801900
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypothyroidism.
    Jayakumar RV
    J Indian Med Assoc; 2006 Oct; 104(10):557-60, 562. PubMed ID: 17380819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation with recombinant human thyroid-stimulating hormone for thyroid remnant ablation with 131I is associated with lowered radiotoxicity.
    Rosário PW; Borges MA; Purisch S
    J Nucl Med; 2008 Nov; 49(11):1776-82. PubMed ID: 18927337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-week thyroxine withdrawal: a thyroid-specific quality of life study.
    Davids T; Witterick IJ; Eski S; Walfish PG; Freeman JL
    Laryngoscope; 2006 Feb; 116(2):250-3. PubMed ID: 16467714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview on the use of recombinant human thyrotropin in thyroid cancer of follicular cell origin.
    Zanotti-Fregonara P; Toubert ME; Taieb D; Ravasi L; Rubello D; Hindie E
    Minerva Endocrinol; 2008 Jun; 33(2):53-65. PubMed ID: 18332849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Thyroid neoplasms: treatment with thyroid hormones after thyroidectomy (author's transl)].
    Horster FA
    Schweiz Rundsch Med Prax; 1982 Apr; 71(16):691-3. PubMed ID: 7111188
    [No Abstract]   [Full Text] [Related]  

  • 19. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
    Jarzab B; Handkiewicz-Junak D; Wloch J
    Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new age for recombinant human thyroid-stimulating hormone?
    Medvedec M
    J Nucl Med; 2009 May; 50(5):832; author reply 832-3. PubMed ID: 19372486
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.